A Single-center Retrospective Study of MIAD ± R Chemotherapy in Newly Diagnosed Primary Central Nervous System Lymphoma: Safety Profiles and Clinical Outcomes.

Authors

Yuedan Chen, Qu Cui, Jun Qian, Xueyan Bai, Ruixian Xing, Jing Liu, Qing Liu, Yuchen Wu, Wenyuan Lai, Huixiu Han, Yuanbo Liu, Xuefei Sun, Lin Fu

Published in

Clinical lymphoma, myeloma & leukemia. Aug 31, 2026. Epub Aug 31, 2026.

Abstract

The optimal induction therapy for primary central nervous system lymphoma (PCNSL) has not been well-established. The aim of this study was to evaluate clinical efficacy and safety of the MIAD ± R (methotrexate, ifosfamide, cytarabine, dexamethasone, and with/without rituximab) regimen in patients with newly diagnosed PCNSL.
In this monocentric retrospective study, we collected clinical data from PCNSL patients treated with MIAD ± R to report our institutional experience with this regimen in real-world practice. Patient demographic and clinical data were analyzed using descriptive statistics. The Kaplan-Meier curves were employed to estimate overall survival (OS) and progression-free survival (PFS).
Eighty-one patients were consecutively included with a median follow-up of 23.1 months (95% confidence interval [CI], 17.6-28.6), among which, 50 (61.7%) patients achieved complete remission (CR), 25 (30.9%) achieved partial remission (PR), 3 (3.7%) had stable disease (SD) and 3 (3.7%) had progression of disease (PD). The objective response rate (ORR) was 92.6%. The median PFS was 11.8 months (95% CI, 4.9-18.7), and the 1-year PFS rate was 49.2%. The median overall survival (OS) was not reached; the 1-year OS rate was 93.5%. Adverse events (AEs) were manageable with standard supportive care; neutropenia (66.7%) and alanine aminotransferase/aspartate aminotransferase elevations (63%) were the most common events. No treatment related death was recorded.
The MIAD ± R regimen is a viable treatment option for newly diagnosed PCNSL with favorable efficacy and an acceptable safety profile. Further prospective trials are warranted to verify its value in the first-line standard of treatment in PCNSL.

PMID:
42786016
Bibliographic data and abstract were imported from PubMed on 25 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.